Endo allies on hybrid drugs

Asubsidiary of Endo is allying with US-based ophthalmics and injectables specialist Nevakar to develop and market five “differentiated” sterile injectable products in the US and Canada. Nevakar will take charge of developing and filing the products, using in the US the 505(b)(2) hybrid new drug application (NDA) pathway.